Page 944 - Adams and Stashak's Lameness in Horses, 7th Edition

910 Chapter 8

118. Ramey DW, Eddington N, Thonar E. An analysis of glucosamine 142. Trumble TN. The use of nutraceuticals for osteoarthritis in
horses. Vet Clin North Am Equine Pract 2005;21:575–597.
and chondroitin sulfate content in oral joint supplement prod- 143. UCVM class of 2016*, Banse H, Cribb AE. Comparative effi-
ucts. J Equine Vet Sci 2002;22:125–127.
VetBooks.ir 119. Redini F, Moczar E, Poupon MF. Effects of glycosaminoglycans 144. Unknown. Joint health supplements for pets (dogs and cats) and
cacy of oral meloxicam and phenylbutazone in 2 experimental
pain models in the horse. Can Vet J 2017;58:157–167.
and extracellular matrix components on metastatic rat rhabdo‐
myosarcoma tumor and myoblast cell proliferation. Clin Exp
Metastasis 1990;8:491–502.
ConsumerLab.com, August 20, 2009.
120. Reed SK, Messer NT, Tessman RK, et al. Effects of phenylbutazone horses with glucosamine, chondroitin. MSM available at www.
alone or in combination with flunixin meglumine on blood protein 145. Unknown. National animal supplement council. http://nasc.cc/
concentrations in horses. Am J Vet Res 2006;67:398–402. index.php, August 20, 2009.
121. Richardson LM, Whitfield‐Cargile CM, Cohen ND, et al. Effect 146. Unknown. Vedaprofen. Summary report. European Agency for
of selective versus nonselective cyclooxygenase inhibitors on the Evaluation of Medicinal Products Veterinary Medicines
gastric ulceration scores and intestinal inflammation in horses. Evaluation Unit. Committee for Veterinary Medicinal prod-
Vet Surg 2018;47:784–791. ucts. http://www.emea.europa.eu/pdfs/vet/mrls/014496en.pdf,
122. Richmond VL. Incorporation of methylsulfonylmethane sulfur July 10, 2009.
into guinea pig serum proteins. Life Sci 1986;39:263–268. 147. Unknown. Natural medicines in the clinical management of
123. Riegel RJ. The correlation of training times, thermographic and osteoarthritis. http://www.naturaldatabase.com, April 2, 2009.
serum chemistry levels to provide evidence as to the effectiveness 148. Unknown. Metacam. Scientific discussion. European Agency for
of the use of oral Alavis MSM (Methylsulfonylmethane) upon the Evaluation of Medicinal Products Veterinary Medicines
the musculature of the racing Standardbred. www.sheld.com/ Evaluation Unit. Committee for veterinary medicinal products.
pdf/msm_race_horse.pdf, August 20, 2009. www.emea.europa.eu/vetdocs/PDFs/EPAR/metacam/032397
124. Rohde C, Anderson DE, Bertone AL, et al. Effects of phenylbuta- en6.pdf, July 10, 2009.
zone on bone activity and formation in horses. Am J Vet Res 149. Usha PR, Naidu MU. Randomized, double‐blind, parallel, pla-
2000;61:537–543. cebo‐controlled study of oral glucosamine, methylsulfonylmeth-
125. Ronca F, Palmieri L, Panicucci P, et al. Anti‐inflammatory activ- ane and their combination in osteoarthritis. Clin Drug Investig
ity of chondroitin sulfate. Osteoarthritis Cartilage 1998;6(Suppl 2004;24:353–363.
A):14–21. 150. Van de Water E, Oosterlinck M, Dumoulin M, et al. The preven-
126. Ross‐Jones TN, McIlwraith CW, Kisiday JD, et al. Influence of tative effects of two nutraceuticals on experimentally induced
an n‐3 long‐chain polyunsaturated fatty acid‐enriched diet on acute synovitis. Equine Vet J 2017;49:532–538.
experimentally induced synovitis in horses. J Anim Physiol Anim 151. Vander Werf KA, Davis EG, Kukanich B. Pharmacokinetics and
Nutr 2016;100:565–577. adverse effects of oral meloxicam tablets in healthy adult horses.
127. Schwartz ER, Adamy L. Effect of ascorbic acid on arylsulfatase J Vet Pharmacol Ther 2012;36:376–381.
activities and sulfated proteoglycan metabolism in chondrocyte 152. Vandeweerd J‐M, Coisnon C, Clegg P, et al. Systemic review of
cultures. J Clin Invest 1977;60:96–106. efficacy of nutraceuticals to alleviate clinical signs of osteoarthri-
128. Setnikar I, Giacchetti C, Zanolo G. Pharmacokinetics of glucosa- tis. J Vet Intern Med 2012;26:448–456.
mine in the dog and in man. Arzneimittelforschung 1986; 153. Verbruggen G. Chondroprotective drugs in degenerative joint
36:729–735. diseases. Rheumatology (Oxford) 2006;45:129–138.
129. Shikhman AR, Kuhn K, Alaaeddine N, et al. N‐acetylglucosa- 154. Walliser U, Fenner A, Mohren N, et al. Evaluation of the efficacy
mine prevents IL‐1 beta‐mediated activation of human chondro- of meloxicam for post‐operative management of pain and
cytes. J Immunol 2001;166:5155–5160. inflammation in horses after orthopaedic surgery in a placebo
130. Silbert JE, Sugumaran G, Cogburn JN. Sulphation of proteo‐ controlled clinical field trial. BMC Vet Res 2015;11:113.
chondroitin and 4‐methylumbelliferyl beta‐D‐xyloside‐chon‐ 155. Wang J, Gao J‐S, Chen J‐W, et al. Effect of resveratrol on carti-
droitin formed by mouse mastocytoma cells cultured in lage protection and apoptosis inhibition in experimental osteo-
sulphate‐deficient medium. Biochem J 1993;296:119–126. arthritis of rabbit. Rheumatol Int 2012;32:1541–1548.
131. Snow DH, Baxter P, Whiting B. The pharmacokinetics of 156. Watts AE, Dabareiner R, Marsh C, et al. A randomized, con-
meclofenamic acid in the horse. J Vet Pharmacol Ther 1981; trolled trial of the effects of resveratrol administration in perfor-
4:147–156. mance horses with lameness localized to the distal tarsal joints.
132. Snow DH, Douglas TA, Thompson H, et al. Phenylbutazone J Am Vet Med Assoc 2016;249:650–659.
toxicosis in equidae: a biochemical and pathophysiological 157. Welsh JC, Lees P, Stodulski G, et al. Influence of feeding schedule
study. Am J Vet Res 1981;42:1754–1759. on the absorption of orally administered flunixin in the horse.
133. Snow DH, Douglas TA, Thompson H, et al. Effect of non‐steroi- Equine Vet J Suppl 1992:62–65.
dal anti‐inflammatory agents on plasma protein concentration 158. White G, Sanders T, Sites T, et al. Efficacy of systemically admin-
of ponies. Vet Res Comm 1983;7:205–206. istered anti‐arthritic drugs in an induced equine carpitis model.
134. Steinmeyer J. Pharmacological basis for the therapy of pain and Proc Am Assoc Equine Pract 1996;42:135–138.
inflammation with nonsteroidal anti‐inflammatory drugs. 159. White GW, Bertone J, Stenbom R, et al. Luitpold animal health
Arthritis Res 2000;2:379–385. roundtable discussion on compounding for the equine veterinary
135. Sugimoto K, Takahashi M, Yamamoto Y, et al. Identification of profession. J Equine Vet Sci 2003;23:517–536.
aggrecanase activity in medium of cartilage culture. J Biochem 160. White GW, Stites T, Jones EW, et al. Efficacy of intramuscular
1999;126:449–455. chondroitin sulfate and compounded acetyl‐d‐glucosamine in a
136. Sullivan M, Snow DH. Factors affecting absorption of nonsteroi- positive controlled study of equine carpitis. Proc Am Assoc
dal anti‐inflammatory agents in the horse. Vet Rec 1982;110: Equine Pract 2004;50:264–269.
554–558. 161. Williams CA, Lamprecht ED. Some commonly fed herbs and
137. Taylor JB, Walland A, Lees P, et al. Biochemical and haemato- other functional foods in equine nutrition: a review. Vet J
logical effects of a revised dosage schedule of phenylbutazone in 2008;178:21–31.
horses. Vet Rec 1983;112:599–602. 162. Willoughby DA, Moore AR, Colville‐Nash PR. COX‐1, COX‐2,
138. Tobin T. Pharmacology review: the non‐steroidal anti‐inflamma- and COX‐3 and the future treatment of chronic inflammatory
tory drugs. II. Equiproxen, meclofenamic acid, flunixin and oth- disease. Lancet 2000;355:646–648.
ers. J Equine Med Surg 1979;3:298–302. 163. Yamanashi S, Toyoda H, Furuya N, et al. Metabolic study on
139. Todhunter RJ. Anatomy and physiology of synovial joints. In chondroitin sulfates in rabbits. Yakugaku Zasshi 1991;111:
Joint Disease in the Horse, 1st ed. McIlwraith CW, Trotter GW, 73–76.
eds. WB Saunders, Philadelphia, 1996;1–28. 164. Zeijdner EE. Digestibility of collagen hydrolysate during passage
140. Traub‐Dargatz JL, Bertone JJ, Gould DH, et al. Chronic flunixin through a dynamic gastric and small intestinal model (TIM‐1).
meglumine therapy in foals. Am J Vet Res 1988;49:7–12. TNO Nutrition and Food Research Report, June 24, 2002.
141. Trujillo O, Rios A, Maldonado R, et al. Effect of oral administra- 165. Ziegler A, Fogle C, Blikslager A. Update on the use of cyclooxy-
tion of acetylsalicylic acid on haemostasis in the horse. Equine genase‐2‐selective nonsteroidal anti‐inflammatory drugs in
Vet J 1981;13:205–206. horses. J Am Vet Med Assoc 2017;250:1271–1274.